id:"swepub:oai:DiVA.org:liu-171952"
Search: id:"swepub:oai:DiVA.org:liu-171952" > Treatment of severe...
- 1 of 1
- Previous record
- Next record
- To hitlist
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials
-
- Han, Young Joo (author)
- Sungkyunkwan Univ, South Korea
-
- Lee, Keum Hwa (author)
- Yonsei Univ, South Korea
-
- Yoon, Sojung (author)
- Yonsei Univ, South Korea
- show more...
- show less...
- (creator_code:org_t)
- IVYSPRING INT PUBL, 2021
- 2021
- English.
- In: Theranostics. - : IVYSPRING INT PUBL. - 1838-7640. ; 11:3, s. 1207-1231
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Rationale: Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a threat to humanity. However, no specific therapy has been established for this disease yet. We conducted a systematic review to highlight therapeutic agents that might be effective in treating COVID-19. Methods: We searched Medline, Medrxiv.org, and reference lists of relevant publications to identify articles of in vitro, in vivo, and clinical studies on treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 published in English until the last update on October 11, 2020. Results: We included 36 studies on SARS, 30 studies on MERS, and 10 meta-analyses on SARS and MERS in this study. Through 12,200 title and 830 full-text screenings for COVID-19, eight in vitro studies, 46 randomized controlled trials (RCTs) on 6,886 patients, and 29 meta-analyses were obtained and investigated. There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19. Remdesivir showed a therapeutic effect for COVID-19 in two RCTs involving the largest number of total participants (n = 1,461). Other therapies that showed an effect in at least two RCTs for COVID-19 were sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), IFN-beta 1b (n = 193), and convalescent plasma therapy (n = 126). Conclusions: This review provides information to help establish treatment and research directions for COVID-19 based on currently available evidence. Further RCTs are required.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- COVID-19; therapeutic agent; SARS; MERS; mortality; coronavirus
Publication and Content Type
- ref (subject category)
- for (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Han, Young Joo
- Lee, Keum Hwa
- Yoon, Sojung
- Nam, Seoung Wan
- Ryu, Seohyun
- Seong, Dawon
- show more...
- Kim, Jae Seok
- Lee, Jun Young
- Yang, Jae Won
- Lee, Jinhee
- Koyanagi, Ai
- Hong, Sung Hwi
- Dragioti, Elena
- Radua, Joaquim
- Smith, Lee
- Oh, Hans
- Abou Ghayda, Ram ...
- Kronbichler, And ...
- Effenberger, Mar ...
- Kresse, Daniela
- Denicolo, Sara
- Kang, Woosun
- Jacob, Louis
- Shin, Hanwul
- Shin, Jae Il
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Theranostics
- By the university
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
